Early Adopters Share Experiences With Grail Cancer Test as Firm Faces New Clinical Questions
Premium
Real-world and trial data shored up evidence that the company's multi-cancer detection assay can guide follow-up assessment of patients with a positive result.
Large Study of Early-Onset Colorectal Cancer Patients IDs Unique, Potentially Actionable Mutations
In younger patients, HER2 mutations were more prevalent in those who had MSI-high/TMB-high tumors, while POLE mutations were more common in MSS/TMB-high tumors, researchers reported at ASCO.
In addition to establishing local teams in Europe and China, the company recently inked distribution agreements for other markets across the world.
Transcriptomics Unravels Role of Interferon Receptors in Down's Syndrome
The findings of a transcriptome analysis of blood from 304 individuals with Down's syndrome and 96 controls have implications for therapeutic development.
The 53-gene biomarker signature showed promise in predicting immunotherapy response in high-risk triple-negative and HR-positive breast cancer.
Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
The companies will develop FoundationOne Liquid CDx and FoundationOne CDx as CDx tests in the US market for selected Merck KGaA marketed and pipeline treatments.